ClearPoint Neuro announced that its Navigation Software Version 3.0.2 has received EU Medical Device Regulation (MDR) certification, granting the company CE marking for the updated platform on January 22, 2026.
The new release adds an intraoperative CT workflow and supports cone‑beam CT imaging, allowing the system to be used in operating rooms that lack intraoperative MRI. This capability broadens the company’s reach to hospitals that previously could not adopt its navigation tools.
The certification expands ClearPoint’s European addressable market and reinforces its position as a comprehensive neurosurgical navigation solution. It also opens cross‑sell opportunities with existing biopharma partners who require a unified global platform for CNS delivery trials.
ClearPoint’s preliminary Q4 2025 revenue reached $10.4 million, a 20% comparable‑sales increase versus Q4 2024, and the company reported a full‑year 2025 revenue of $37 million. Management has guided 2026 revenue to $54–$60 million, driven by organic growth and the integration of the IRRAS product line. The acquisition of IRRAS Holdings for $5 million in cash and 1,325,000 shares is expected to enhance commercial scale and operational leverage.
Segment performance in Q4 2025 showed strong growth in functional neurosurgery disposables (+23%) and biologics and drug delivery (+26%). Earlier in the year, Q1 2025 revenue was $8.5 million, while Q3 2025 revenue fell to $5.36 million, reflecting fewer new placements and installation timing challenges that impacted capital‑equipment and software revenue.
Chief Operating Officer Mazin Sabra said the CE Mark will enable consistent training and hospital IT support, helping biopharma partners achieve global consistency. President and CEO Joe Burnett expressed confidence in the company’s momentum heading into 2026, citing the expanded platform and pipeline of new products.
The announcement was well received by investors, who noted the company’s ability to unify its global navigation platform, reduce operating costs, and capitalize on a broader European market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.